MediciNova Inc., a biopharmaceutical company listed on the NASDAQ and the Tokyo Stock Exchange, has provided an update on the enrollment status of two major clinical trials involving its developmental compounds MN-166 (ibudilast) and MN-001 (tipelukast). The ongoing Phase 2/3 COMBAT-ALS trial is nearing completion with only a single digit number of patients remaining to be randomized. In parallel, the Phase 2 trial targeting dyslipidemia and fatty liver disease in type 2 diabetes patients is seeking its final two participants. MediciNova anticipates top-line data from the ALS trial by the end of next year and is preparing for discussions with the FDA. Results for these trials have not yet been presented.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。